HC Wainwright Expects Reduced Earnings for Alpha Tau Medical

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – HC Wainwright decreased their FY2025 EPS estimates for shares of Alpha Tau Medical in a report issued on Monday, March 17th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.53) per share for the year, down from their prior estimate of ($0.50). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.45) per share.

Alpha Tau Medical (NASDAQ:DRTS) last posted its earnings results on Wednesday, March 12th. The company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13).

Alpha Tau Medical Trading Down 1.5 %

DRTS opened at $2.62 on Wednesday. The stock has a fifty day simple moving average of $3.25 and a two-hundred day simple moving average of $2.80. The company has a market cap of $183.20 million, a price-to-earnings ratio of -6.09 and a beta of 0.87. Alpha Tau Medical has a 12-month low of $1.75 and a 12-month high of $4.39.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DRTS. Levin Capital Strategies L.P. grew its holdings in Alpha Tau Medical by 2.3% in the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock worth $975,000 after purchasing an additional 7,189 shares during the period. Northern Trust Corp boosted its position in shares of Alpha Tau Medical by 112.6% in the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock worth $151,000 after purchasing an additional 25,770 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Alpha Tau Medical by 188.7% in the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock worth $127,000 after buying an additional 26,800 shares during the last quarter. 2.65% of the stock is currently owned by institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.